Evogen Moves Into Molecular Diagnostics With Initial Focus on Epilepsy | GenomeWeb

NEW YORK (GenomeWeb) – Biotech firm Evogen is moving from its traditional focus on infectious disease threat detection to precision medicine and molecular diagnostics, with a primary emphasis on neurology.

The company's first product in this area is the EvoScore START test, a blood-based proteomic assay intended to help doctors distinguish epileptic seizures from seizures with other causes. According to Todd Wallach, Evogen's president and CEO, the company plans to launch the diagnostic in targeted markets as a laboratory-developed test in 2017.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.